JMP Group Expands Life Sciences Investment Banking and Equity Research Platforms
January 25 2021 - 4:15PM
Business Wire
Fedora Baloiu, Silvan Tuerkcan and Gobind Singh
Join JMP Securities
JMP Group LLC (NYSE: JMP), an investment banking and alternative
asset management firm, announced today that Fedora Baloiu has
joined JMP Securities as a managing director and co-head of
biopharma corporate finance. Additionally, Silvan Tuerkcan and
Gobind Singh, a director and vice president, respectively, have
both joined JMP Securities as senior equity research analysts
focused on the biotechnology sector. All three are based in the
firm’s New York office.
In connection with these key additions to JMP Securities’ life
sciences franchise, David Kellman, a managing director and head of
healthcare investment banking, will also serve as co-head of
biopharma corporate finance, while David Schechner, a managing
director in the healthcare investment banking group, has been named
head of biopharma mergers and acquisitions.
“We could not be more enthusiastic about the recent developments
in our healthcare group,” said Mark Lehmann, chief executive
officer of JMP Securities. “JMP has long been well recognized
within the life sciences industry for its equity research and
investment banking capabilities, and our platform is now broader
than ever before. Our three newest additions will be immediate
contributors. Fedora brings longstanding relationships and
excellent perspective on the healthcare capital markets, while
Silvan and Gobind have already begun to complement our existing
biotech research with initial coverage of their own. As a result,
we are positioned to build on our success, making our firm an even
greater resource for our corporate and institutional clients in the
life sciences space.”
Prior to joining JMP Securities, Ms. Baloiu was a managing
director and head of U.S. healthcare investment banking at Nomura
Securities. She previously served as head of the biopharmaceuticals
practice at Houlihan Lokey, after spending nearly a decade in the
healthcare investment banking division at Goldman Sachs & Co.
Ms. Baloiu began her career as a consultant at Bain & Company
in Milan, Italy. She holds a master’s degree in biotechnology from
Johns Hopkins University, an MBA from Columbia Business School, and
an undergraduate business degree from Italy’s Bocconi
University.
Prior to joining JMP Securities, Mr. Tuerkcan was an executive
director and senior research analyst covering biotechnology at both
UBS and Oppenheimer & Co. He previously worked in equity
research at Goldman Sachs & Co. Mr. Tuerkcan began his career
as a postdoctoral fellow both at Institut Pasteur & Ecole
Polytechnique in France and later at the Stanford University School
of Medicine. He holds a PhD in biophysics from France’s Ecole
Polytechnique, an MSc in engineering physics from Germany’s TU
Munich, and a BSc in physics from Canada’s McGill University.
Prior to joining JMP Securities, Mr. Singh worked in equity
research at BMO Capital Markets, with a focus on the biotechnology
sector. Before starting his financial services career, Mr. Singh
engaged in clinical practice and academic research while a
physician at nationally recognized medical centers such as UCSF. He
holds MD and PhD degrees from Mount Sinai School of Medicine and an
undergraduate degree with concentrations in chemistry,
biochemistry, and biology from Boston University.
JMP Securities is a full-service, middle-market investment bank
with a healthcare practice consisting of five senior investment
bankers, a dedicated senior capital markets professional, and seven
equity research analysts covering biotechnology,
biopharmaceuticals, and medical devices and supplies. The firm’s
healthcare investment banking group executed 51 capital raising and
strategic advisory transactions with an aggregate value of $6.1
billion in 2020.
About JMP Group
JMP Group LLC is a diversified capital markets firm that
provides investment banking, equity research, and sales and trading
services to corporate and institutional clients as well as
alternative asset management products and services to institutional
and high-net-worth investors. JMP Group conducts its investment
banking and research, sales, and trading activities through JMP
Securities; its venture capital and private capital activities
through Harvest Capital Strategies and JMP Asset Management; and
the management of Harvest Capital Credit Corporation (NASDAQ:
HCAP), a business development company, through HCAP Advisors. For
more information, visit www.jmpg.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210125005717/en/
Investor Relations Contact JMP Group LLC
Andrew Palmer (415) 835-8978 apalmer@jmpg.com
Media Relations Contacts Dukas Linden Public Relations,
Inc.
Zach Leibowitz (646) 722-6528 zach@dlpr.com
Michael Falco (646) 808-3611 michael@dlpr.com
JMP (NYSE:JMP)
Historical Stock Chart
From Aug 2024 to Sep 2024
JMP (NYSE:JMP)
Historical Stock Chart
From Sep 2023 to Sep 2024